Physician profile
Colleen E Johnson
NPI 1942471164
$2,536.50
in general payments reported to CMS, 2019-2025
20 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $871 · 2023: $557 · 2024: $440 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.62 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $203.63 | 2021-2024 | Stelara |
| Ironwood Pharmaceuticals, INC | $119.14 | 2022-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $108.03 | 2022-2025 | Entyvio, Eohilia |
| Celgene Corporation | $97.24 | 2021-2023 | Zeposia |
| Amgen INC. | $77.29 | 2022-2023 | Avsola, Amjevita |
| Pfizer INC. | $76.69 | 2021 | |
| Ardelyx, INC. | $65.34 | 2022-2023 | Ibsrela |
| Novo Nordisk INC | $59.02 | 2025 | Wegovy |
| Gilead Sciences, INC. | $35.91 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $29.61 | 2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $29.50 | 2022 | |
| Genzyme Corporation | $27.64 | 2025 | |
| Intercept Pharmaceuticals, INC. | $27.07 | 2023 | Ocaliva |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.99 | 2022 | |
| Braintree Laboratories, INC. | $21.62 | 2021 | |
| Pharmacosmos Therapeutics INC. | $19.30 | 2023 | Monoferric |
| Qol Medical, LLC | $15.61 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.92 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.